Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R.

Oncotarget. 2012 Dec;3(12):1566-75.

2.

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R.

Cancer Res. 2013 Jan 1;73(1):276-84. doi: 10.1158/0008-5472.CAN-12-1726. Epub 2012 Oct 12.

3.

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R.

Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.

4.

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R.

Mol Cancer Ther. 2013 Dec;12(12):2857-63. doi: 10.1158/1535-7163.MCT-13-0319-T. Epub 2013 Oct 3.

5.

KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.

Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R.

PLoS One. 2012;7(5):e38033. doi: 10.1371/journal.pone.0038033. Epub 2012 May 31.

6.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
7.

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R.

PLoS One. 2011;6(7):e22769. doi: 10.1371/journal.pone.0022769. Epub 2011 Jul 29.

8.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
9.

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.

Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yamanaka T, Doi T, Ohtsu A, Yoshino T.

BMC Cancer. 2015 Apr 11;15:258. doi: 10.1186/s12885-015-1276-z.

10.

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R.

J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23.

11.

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.

BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.

12.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y.

PLoS One. 2013 Dec 10;8(12):e81628. doi: 10.1371/journal.pone.0081628. eCollection 2013.

13.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.

Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.

PMID:
20619739
14.

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.

Takahashi N, Yamada Y, Taniguchi H, Fukahori M, Sasaki Y, Shoji H, Honma Y, Iwasa S, Takashima A, Kato K, Hamaguchi T, Shimada Y.

BMC Res Notes. 2014 Apr 29;7:271. doi: 10.1186/1756-0500-7-271.

15.

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R.

Ann Oncol. 2013 Aug;24(8):2158-65. doi: 10.1093/annonc/mdt115. Epub 2013 Apr 10.

16.

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2013 Dec 4;105(23):1789-98. doi: 10.1093/jnci/djt298. Epub 2013 Nov 14.

17.

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J.

Mol Cancer Ther. 2012 Sep;11(9):2062-71. doi: 10.1158/1535-7163.MCT-12-0290. Epub 2012 Jun 21.

18.

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.

Emile JF, Diamond EL, Hélias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman DM, Kim E, Rampal R, Patel M, Ganzel C, Aumann S, Faucher G, Le Gall C, Leroy K, Colombat M, Kahn JE, Trad S, Nizard P, Donadieu J, Taly V, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2014 Nov 6;124(19):3016-9. doi: 10.1182/blood-2014-04-570937. Epub 2014 Aug 22.

19.

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.

Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y.

BMC Cancer. 2014 Nov 3;14:802. doi: 10.1186/1471-2407-14-802.

20.

A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.

Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.

BJU Int. 2012 Dec;110(11 Pt C):E1237-48. doi: 10.1111/j.1464-410X.2012.11569.x. Epub 2012 Oct 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk